Kosten-Kosten-Studie zur parenteralen Eisentherapie bei Eisenmangelanämie in der ambulanten Versorgung der GKV in Deutschland

Bierbaum, Matthew; Schöffski, Oliver

doi:10.1055/s-0032-1330649

Cited by 5 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 We thus considered that all treated patients received an administration of up to 1000 mg (maximal dose per administration) of FCM in the beginning of each year via one ambulatory consultation before death. Moreover, a real-world study carried out in Germany reported that annual doses of 925 mg per patient were used.…”

Section: Cost Parametersmentioning

confidence: 99%

“…Moreover, a real-world study carried out in Germany reported that annual doses of 925 mg per patient were used. 26 We thus considered that all treated patients received an administration of up to 1000 mg (maximal dose per administration) of FCM in the beginning of each year via one ambulatory consultation before death. We assigned the ambulatory administrations at the beginning of each year in order to simplify the model and to be able to capture patients who transition to the state of death during the first transition period of each year and thus cannot be treated afterwards.…”

Section: Cost Parametersmentioning

confidence: 99%

See 1 more Smart Citation

Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France

et al. 2019

View full text Add to dashboard Cite

Aims This analysis aims to evaluate the budget impact of intravenous iron therapy with ferric carboxymaltose for patients with systolic chronic heart failure and iron deficiency, from the perspective of the French public health insurance. Methods and results A budget impact model was adapted to forecast the budget impact over 5 years, according to two scenarios: one where patients receive ferric carboxymaltose according to market share forecast and another where patients are not treated for iron deficiency. Clinical data were extrapolated from pooled data from four randomized controlled trials. The time horizon was extended to 5 years by applying transition probabilities estimated from the CONFIRM‐HF trial. Epidemiological parameters for France were derived from the literature. Cost parameters were derived from national available databases. In the base case analysis, the modelled 5 year cost difference between the scenarios with ferric carboxymaltose vs. no iron deficiency treatment in a population of 189 334 prevalent and incident patients led to €0.8m savings. The cumulative savings resulted from a reduction in the hospitalization costs associated with worsening heart failure (€−35.8m) as well as a reduction in the follow‐up costs (€−2.9m). These cost savings outweighed the costs of ferric carboxymaltose treatment (€37.7m). Sensitivity analyses showed that the budget impact varied from €−34m to €+146m. Parameters with the most impact on the budget were the hospitalization rate for patients not treated for iron deficiency, the number of ambulatory sessions needed, the absence of hospitalization cost differentiation between New York Heart Association classes, and administration settings costs. Conclusions Iron deficiency treatment with ferric carboxymaltose in systolic chronic heart failure patients results in an improvement of New York Heart Association class and thereby increases the well‐being of the patients, while providing an overall cost saving for the French national health insurance.

show abstract

Section: Cost Parametersmentioning

confidence: 99%

Section: Cost Parametersmentioning

confidence: 99%

Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France

et al. 2019

View full text Add to dashboard Cite

show abstract

“…When only treating patients in NYHA class III or II, therapy with FCM leads to net budget impact of −€110 380 or €321 137 compared with no-iron treatment. Assuming the same clinical effects and using real-world data for mean FCM dose of 925 mg, taken from a real-world study by Bierbaum et al, 23 the annual FCM costs will be €292 957, and the net budget impact changes to −€198 768 demonstrating cost savings. Changing the FCM price by 25%, the budget impact ranges from €173 495 (price +25%) to −€92 626 (price −25%).…”

Section: Sensitivity Analysismentioning

confidence: 99%

“…Mean cumulative dose used in the model was 1679 mg given in 2.1 applications. Assuming annual real-life dose of 925 mg per patient, taken from a real-world study of Bierbaum et al, 23 the annual FCM costs would decrease by 45% per patient and treatment with FCM would be net cost saving compared with no-iron. Excluding the usual €10 copayment by the patients himself for a 1000 mg package of FCM, the price would decrease to €306.71, and budget impact of FCM treatment would decrease to €23 per treated patient compared with a no-iron therapy.…”

Section: Limitationsmentioning

confidence: 99%

See 1 more Smart Citation

Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany

Theidel¹,

Väätäinen

Martikainen

et al. 2017

ESC Heart Failure

View full text Add to dashboard Cite

AimsTreatment of iron deficiency (ID) in patients with heart failure (HF) with intravenous iron substitution [ferric carboxymaltose (FCM)] has previously shown significant improvements in exercise capacity, New York Heart Association (NYHA) functional class, quality of life, and reduction of hospitalization. The aim of this study was to estimate the budget impact of FCM treatment for patients with HF and ID.Methods and resultsIndividual patient data from four double‐blind randomized controlled trials were pooled for this analysis. Expected outcomes were modelled for a treatment period of 1 year, using multivariate statistical methods. Associated unit costs were derived from claims data. Budget impact was calculated from the perspective of the Statutory Health Insurance. Multiple deterministic sensitivity analyses were performed. The annual budget impact for therapy with FCM vs. no‐iron therapy was €2 735 505 and €2 695 474 for 1000 patients, respectively, resulting in additional annual costs of €40.03 for each treated patient. Main costs drivers are the FCM treatment cost and cost of hospitalizations due to HF worsening. FCM therapy compared with no‐iron therapy resulted in reduced cost per 1000 patients: for reduced hospitalization due to HF worsening (52 vs. 129 hospitalizations amounting to €230 591 vs. €597 078), for reduced other medication (€1 611 007 vs. €1 679 908), fewer outpatient visits (€332 523 vs. €378 019), and home visits (€29 627 vs. €40 469). Sensitivity analyses showed robustness of the results.ConclusionsTherapy with FCM has a minimal budget impact of €40 031 per 1000 patients per year. This budget impact translates into reduced and shorter hospitalizations and improved symptomatic status of the patients.

show abstract

Verschiedene Szenarien zu Abrechnung und Kostenerstattung eines präoperativen Managements der Eisenmangelanämie im deutschen Gesundheitssystem

et al. 2019

View full text Add to dashboard Cite

Kosten-Kosten-Studie zur parenteralen Eisentherapie bei Eisenmangelanämie in der ambulanten Versorgung der GKV in Deutschland

Cited by 5 publications

References 5 publications

Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France

Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France

Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany

Verschiedene Szenarien zu Abrechnung und Kostenerstattung eines präoperativen Managements der Eisenmangelanämie im deutschen Gesundheitssystem

Contact Info

Product

Resources

About